# Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

> **NCT06855589** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Charles LeMoyne Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)

## Interventions

- **DRUG:** 6 months of Eligard
- **DRUG:** 12 months of Eligard
- **RADIATION:** prostate SBRT or prostate brachytherapy with radiation therapy

## Key facts

- **NCT ID:** NCT06855589
- **Lead sponsor:** Charles LeMoyne Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2033-03
- **Final completion:** 2034-03
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06855589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06855589, "Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06855589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*